Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Gap Down – Time to Sell?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) gapped down before the market opened on Wednesday . The stock had previously closed at $39.75, but opened at $32.72. Supernus Pharmaceuticals shares last traded at $34.98, with a volume of 255,949 shares.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald cut Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $57.00 to $36.00 in a report on Wednesday.

Supernus Pharmaceuticals Trading Down 16.2 %

The stock has a market cap of $1.84 billion, a PE ratio of 31.25 and a beta of 0.90. The business has a fifty day simple moving average of $37.64 and a two-hundred day simple moving average of $35.28.

Insider Buying and Selling at Supernus Pharmaceuticals

In related news, VP Padmanabh P. Bhatt sold 9,477 shares of the firm’s stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total transaction of $376,236.90. Following the sale, the vice president now owns 10,149 shares of the company’s stock, valued at $402,915.30. This trade represents a 48.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 9.30% of the company’s stock.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of SUPN. Raiffeisen Bank International AG purchased a new stake in shares of Supernus Pharmaceuticals in the 4th quarter valued at approximately $25,000. GF Fund Management CO. LTD. acquired a new stake in shares of Supernus Pharmaceuticals in the fourth quarter worth approximately $42,000. Smartleaf Asset Management LLC boosted its position in Supernus Pharmaceuticals by 219.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock worth $47,000 after purchasing an additional 870 shares during the period. Mark Sheptoff Financial Planning LLC purchased a new stake in Supernus Pharmaceuticals during the 4th quarter worth approximately $52,000. Finally, Headlands Technologies LLC increased its stake in Supernus Pharmaceuticals by 203.0% during the fourth quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company’s stock valued at $55,000 after purchasing an additional 1,015 shares during the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.